Shanghai Obio Technology (Group) Corp., Ltd. (SHANGHAI OBIO TECH (GROUP) CORP) Aktie

Shanghai Obio Technology (Group) Corp., Ltd., a biotechnology company, engages in the provision of technical services for the field of regenerative medicine and anti-aging in China. The company offers customized plasmid design and viral vector packaging services; AAV serotypes and tissue-specific promoters to support scientific research; and research grade, NHP Grade, cGMP grade vector manufacturing process, for basic research, translational research and clinical trials. It also provides CDMO services encompassing process development, analytical methods, IND-enabling chemistry, manufacturing, and controls; and clinical and commercial manufacturing for viral vector, oncolytic virus, and cell therapy products. The company was formerly known as Obio Technology (Shanghai) Corp., Ltd. and change its name to Shanghai Obio Technology (Group) Corp., Ltd. in March 2026. The company was founded in 2013 and is headquartered in Shanghai, China.